Upstream Bio (UPB) Other Accumulated Expenses (2024 - 2025)
Upstream Bio's quarterly Other Accumulated Expenses came in at $55000.0 in Q3 2025, down 53.39% year-on-year from $118000.0 in Q3 2024, and down 53.39% quarter-over-quarter from $118000.0 in Q3 2024.
Upstream Bio has reported Other Accumulated Expenses for 2 years, with the latest figure at $55000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 55,000.00 |
| Sep 30, 2024 | 118,000.00 |